RxDoctor Payments Data

Amy Wynne

Nurse Practitioner · Hammond, LANPI 1710245691

Payments from drug & device makers

$1,690in general payments, 2019–2025

Across 74 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$432
  • Johnson & Johnson$242
  • AstraZeneca$240
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$168
  • Paratek Pharmaceuticals, Inc.$128
  • Boehringer Ingelheim$87
  • plus $393 from 12 others

What the payments were for

  • Food & beverage$1,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,690 in reported general payments places this provider in the 75th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$26,313
Medicare patients
124
Services billed
331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$38,468
EntrestoSacubitril/Valsartan26$13,818
JardianceEmpagliflozin19$12,358
FarxigaDapagliflozin Propanediol13$7,131
Nifedipine ErNifedipine25$427
Atorvastatin Calcium42$419
Metoprolol Succinate43$400
Amiodarone Hcl36$374
ClopidogrelClopidogrel Bisulfate31$219
Cefdinir13$146
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$95
Pantoprazole Sodium13$82
Metoprolol Tartrate22$82
Carvedilol21$71
Furosemide22$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$432$38,46865 claims
NovartisEntresto$38$13,81826 claims
Boehringer IngelheimJardiance$87$12,35819 claims
AstraZenecaFarxiga$240$7,13113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →